Related Experiment Videos
Growth hormone binding protein in patients with renal failure
H G Maheshwari1, I Rifkin, J Butler
1Department of Clinical Biochemistry, King's College School of Medicine and Dentistry, London, UK.
Acta Endocrinologica
|December 1, 1992
Summary
Growth hormone binding protein (GH-BP) levels are significantly reduced in patients with renal disease, regardless of dialysis status or transplant. This decrease may suggest reduced growth hormone receptor expression and diminished growth hormone responsiveness in kidney failure.
Area of Science:
- Endocrinology
- Nephrology
- Biochemistry
Background:
- Growth hormone binding protein (GH-BP) plays a crucial role in regulating growth hormone (GH) bioavailability.
- Renal disease can impact various hormonal systems, but its effect on GH-BP is not fully understood.
Purpose of the Study:
- To investigate the concentration of GH-BP in individuals with varying stages of renal disease.
- To explore the relationship between GH-BP levels and renal function.
Main Methods:
- Gel chromatography was employed to quantify GH-BP by measuring the percentage of 125I-GH bound to GH-BP.
- Scatchard analysis and receptor binding studies were performed to assess binding affinity and potential inhibitory factors in uremic serum.
Main Results:
- Normal individuals exhibited a GH-BP binding of 39.3 +/- 8.0%.
- Patients with renal disease showed significantly reduced GH-BP binding: 16.8 +/- 5.6% (off dialysis), 24.6 +/- 6.8% (hemodialysis), 25.7 +/- 7.6% (peritoneal dialysis), and 25.1 +/- 8.6% (post-transplant).
- Affinity of GH-BP for GH and binding inhibition by uremic serum were not identified as causes for the reduction.
Conclusions:
- Concentrations of GH-BP are markedly decreased in patients with renal disease across different treatment modalities.
- The reduced GH-BP levels may indicate a downregulation of GH receptors in target tissues.
- This suggests a potential for diminished growth hormone responsiveness in individuals with kidney failure.